Eisai Co. Ltd. and Biogen Idec Inc. have teamed up in Alzheimer's disease to spread the risk across a portfolio of programs investigating several therapeutic hypotheses.

The deal, announced on March 5, gives Eisai financial support for two of its clinical AD programs - BAN2401 and E2609 - plus a future opportunity to include two Biogen programs with different MOAs.